TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05744375

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan
Description: All patients enrolled will be treated with trastuzumab deruxtecan (T-DXd) 5.4 mg/kg IV every 3 weeks (± 3 days).~The subject's weight at baseline will be used to calculate the initial dose. If during the course of treatment the subject's weight changes by ± 10% of the baseline weight, the subject's dose will be recalculated based on the subject's updated weight.~Patients will receive T-DXd until unacceptable toxicity, progressive disease (PD), informed consent withdrawal, or other discontinuation criterion is met.
Study: NCT06207981

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Concomitant chemotherapy (Capecitabin + Mitomycin-C)
Description: Concomitant Chemotherapy consists of Mitomycin-C (10 mg/m2 intravenous infusion at D1 and D29) and Capecitabine (1650 mg/m²/day divided in two oral intakes 825 mg/m² twice a day, five days a week). Patients should be counseled to only take capecitabine on the days when radiotherapy is being given

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Concomitant chemotherapy (Capecitabin + Mitomycin-C)
Description: Concomitant Chemotherapy consists of Mitomycin-C (10 mg/m2 intravenous infusion at D1 and D29) and Capecitabine (1650 mg/m²/day divided in two oral intakes 825 mg/m² twice a day, five days a week). Patients should be counseled to only take capecitabine on the days when radiotherapy is being given

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiotherapy
Description: Radiotherapy consists of conformational intensity-modulated external irradiation with simultaneous integrated boost (IMRT-SIB) with 2 level of dose (30 sessions)~* 49.5 Gy (5 x 1.65 Gy/week) to the pelvis~* 60 Gy (5 x 2 Gy /week) to the primary tumor and initially involved nodes

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiotherapy
Description: Radiotherapy consists of conformational intensity-modulated external irradiation with simultaneous integrated boost (IMRT-SIB) with 2 level of dose (30 sessions)~* 49.5 Gy (5 x 1.65 Gy/week) to the pelvis~* 60 Gy (5 x 2 Gy /week) to the primary tumor and initially involved nodes
Study: NCT05551676

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: transforaminal group
Description: Epidural steroid injection will be applied with transforaminal approach accompanied by fluoroscopy.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lateral parasagittal group
Description: Epidural steroid injection will be applied with lateral parasagittal approach accompanied by scopy.
Study: NCT05351723

Intervention type: OTHER
Group type: OTHER
Intervention: Exercise + cognitive training + education
Description: The research team will record videos for the Intervention group. The intervention procedure includes 3 sections: (1) 50 min of physical exercise, (2) 20 min of break time or lecture on dementia and lifestyle habits, and (3) 50 min of cognitive training. Investigators will be recruited from the National Geriatrics Hospital and trained the technicians for 1 week.~Prior to intervening, patients who agree to participate will be screened and evaluated cognitive function, physical function, assessment of Activities of Daily Living, quality of life, depression, anxiety, stress, and sleep quality.~Technicians will record every training session, monitor participants' health, and ensure that those in the intervention group do the exercises correctly.~We will evaluate the participants in the group after 3 months and after 6 months of intervention.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise + cognitive training + education
Description: The research team will record videos for the Intervention group. The intervention procedure includes 3 sections: (1) 50 min of physical exercise, (2) 20 min of break time or lecture on dementia and lifestyle habits, and (3) 50 min of cognitive training. Investigators will be recruited from the National Geriatrics Hospital and trained the technicians for 1 week.~Prior to intervening, patients who agree to participate will be screened and evaluated cognitive function, physical function, assessment of Activities of Daily Living, quality of life, depression, anxiety, stress, and sleep quality.~Technicians will record every training session, monitor participants' health, and ensure that those in the intervention group do the exercises correctly.~We will evaluate the participants in the group after 3 months and after 6 months of intervention.
Study: NCT06509581

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: vitamin E
Description: Vitamin E will be taken for 12 months for beta thalassemia patiens on regular packed red blood cell transfusion and chelators(desferoxamine,deferiprone and deferasirox )

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO
Description: placebo will be taken for 12 months for beta thalassemia patiens on regular packed red blood cell transfusion and chelators(desferoxamine,deferiprone and deferasirox )
Study: NCT05982275

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: CARTemis-1
Description: A dose escalation design will be applied in successive patient cohorts until identification of Dose Limiting Toxicity (maximum dose: 6x10\^6 CAR-T/kg divided over 2 days).
Study: NCT05628051

Intervention type: PROCEDURE
Intervention: ultrasonographic measurement of carotid artery corrected flow time (FTc)
Description: Ultrasonic measurement of carotid corrected blood flow time: 1. Patient's head turned to the left 30°. Firstly, the 6.0 \~ 13.0MHz linear probe was placed longitudinally on the maternal neck, and the probe marker was oriented towards the maternal head. Real-time B-ultrasound images of the long axis of the right common carotid artery were obtained from the lower margin of the thyroid cartilage. Then, the probe was placed in the center of the carotid lumen, about 2cm from the bifurcation of the carotid artery, to obtain the arterial pulse Doppler flow spectrum and store the carotid flow waveform. 2. Using the caliper function of the ultrasonic instrument, carotid flow time (FT) was obtained by measuring the interval between the systolic ascending stage and the restroke notch. Wodey (W) formula to calculate FTc. FTc= FT+\[1.29× (HR-60)

Intervention type: PROCEDURE
Intervention: ultrasonographic measurement of carotid artery corrected flow time (FTc)
Description: Ultrasonic measurement of carotid corrected blood flow time: 1. Patient's head turned to the left 30°. Firstly, the 6.0 \~ 13.0MHz linear probe was placed longitudinally on the maternal neck, and the probe marker was oriented towards the maternal head. Real-time B-ultrasound images of the long axis of the right common carotid artery were obtained from the lower margin of the thyroid cartilage. Then, the probe was placed in the center of the carotid lumen, about 2cm from the bifurcation of the carotid artery, to obtain the arterial pulse Doppler flow spectrum and store the carotid flow waveform. 2. Using the caliper function of the ultrasonic instrument, carotid flow time (FT) was obtained by measuring the interval between the systolic ascending stage and the restroke notch. Wodey (W) formula to calculate FTc. FTc= FT+\[1.29× (HR-60)
Study: NCT06136572

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Rathus Assertiveness scale
Description: Questionnaire completion
Study: NCT05999526

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reconnection to mechanical ventilation for 1 hour
Description: As soon as the success of the spontaneous breathing trial is confirmed, the participant will be kept on the mechanical ventilator for 1 hour using the previous ventilatory parameters and, afterwards, extubated.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Direct extubation
Description: The participant will be extubated immediately after the spontaneous breathing trial.
Study: NCT05655143

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Balance training
Description: Participants will undergo a 4-week balance training protocol modified from that described previously.~Participants will undergo supervised exercise three times per week for approximately 30 minutes per session. The exercise consists of single-leg balance training, hop to stabilization, and hop to stabilization plus reaching activities as presented in Figure 1. Particularly, the levels of difficulty will be progressed with visual conditions (eyes open and eyes closed), time (sec), and base of support (floor and foam pad) while hopping distance (inches) for single-leg and hopping activities, respectively. These activities will be progressed in difficulty as participants become proficient at the task.
Study: NCT06502509

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Commercial Kombucha tea (Brand name E-Ben Organic Kombucha Lemon)
Description: Commercial lemon kombucha tea (Brand:E-Ben Organic Kombucha Lemon), which will be given to participants in opaque bottles for 8 weeks.
Study: NCT06453603

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRP injection
Description: Receive pes anserinus PRP injection
Study: NCT05318599

Intervention type: DEVICE
Intervention: Lung auscultation
Description: Digital lung auscultation with the Eko core digital stethoscope (Eko Devices, Inc., CA, USA).

Intervention type: DEVICE
Intervention: Lung auscultation
Description: Digital lung auscultation with the Eko core digital stethoscope (Eko Devices, Inc., CA, USA).

Intervention type: DEVICE
Intervention: Lung auscultation
Description: Digital lung auscultation with the Eko core digital stethoscope (Eko Devices, Inc., CA, USA).

Intervention type: DEVICE
Intervention: Lung auscultation
Description: Digital lung auscultation with the Eko core digital stethoscope (Eko Devices, Inc., CA, USA).

Intervention type: DEVICE
Intervention: Lung ultrasound
Description: Lung ultrasonography

Intervention type: DEVICE
Intervention: Lung ultrasound
Description: Lung ultrasonography

Intervention type: DEVICE
Intervention: Lung ultrasound
Description: Lung ultrasonography

Intervention type: DEVICE
Intervention: Lung ultrasound
Description: Lung ultrasonography

Intervention type: OTHER
Intervention: Quality of Life's questionnaires
Description: Impact of the diseases on subjects' health-related quality of life measured with standardized questionnaires (K-BILD, CAT)

Intervention type: OTHER
Intervention: Quality of Life's questionnaires
Description: Impact of the diseases on subjects' health-related quality of life measured with standardized questionnaires (K-BILD, CAT)

Intervention type: OTHER
Intervention: Quality of Life's questionnaires
Description: Impact of the diseases on subjects' health-related quality of life measured with standardized questionnaires (K-BILD, CAT)

Intervention type: OTHER
Intervention: Quality of Life's questionnaires
Description: Impact of the diseases on subjects' health-related quality of life measured with standardized questionnaires (K-BILD, CAT)

Intervention type: DIAGNOSTIC_TEST
Intervention: Pulmonary functional tests
Description: Spirometry, body-plethysmographic parameters and lung diffusion capacity for carbon monoxide will be measured.

Intervention type: DIAGNOSTIC_TEST
Intervention: Pulmonary functional tests
Description: Spirometry, body-plethysmographic parameters and lung diffusion capacity for carbon monoxide will be measured.
Study: NCT05396235

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MT-3921
Description: Solution for infusion; Intravenous (IV)
Study: NCT05318599

Intervention type: DIAGNOSTIC_TEST
Intervention: Pulmonary functional tests
Description: Spirometry, body-plethysmographic parameters and lung diffusion capacity for carbon monoxide will be measured.

Intervention type: DIAGNOSTIC_TEST
Intervention: Pulmonary functional tests
Description: Spirometry, body-plethysmographic parameters and lung diffusion capacity for carbon monoxide will be measured.
Study: NCT06453603

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: corticosteroid injection
Description: Receive pes anserinus corticosteroid injection
Study: NCT06235788

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental Group ICEMS verbal feedback with pause group
Description: While performing the simulated procedure, if participants receive real-time verbal feedback based on the intelligent system error detection, they will be instructed to pause the task, putting their instruments down and reflecting for 22 seconds. A warning will be given when there are 7 seconds remaining in the reflection period so individuals can prepare to resume the task immediately.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental Group ICEMS audio feedback with pause and expert video
Description: While performing the simulated procedure, if participants receive real-time verbal feedback based on the intelligent system error detection, they will be instructed to pause the task, putting their instruments down, turning their attention to a 9-second expert-level demonstration video, and reflecting for 13 seconds. A warning will be given when there are 7 seconds remaining in the reflection period so individuals can prepare to resume the task immediately.
Study: NCT06464094

Intervention type: OTHER
Group type: OTHER
Intervention: User-testing of Vitaliti Continuous Vital Sign Monitor Model CVSM-1A
Description: Single group enrollment to examine user-acceptance and user experiences, while soliciting user feedback on wearability compliance (patient) and proposed clinical workflows using the most recent Vitaliti™ CVSM device.
Study: NCT06143007

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BB3008 tablet
Description: BB3008 tablets will be administered orally once daily (QD).
Study: NCT05396235

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Solution for infusion; Intravenous (IV)
Study: NCT05721976

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: With Love, Grandma (Con Cariño, Abuelita)
Description: Cancer survivor-Daughter dyads will log in to a secured website to access intervention content over a period of 10-12 weeks. The intervention will be delivered primarily through smartphones and will include 8 modules with didactic content on healthy lifestyle behaviors for cancer prevention and control, family behavior change content for setting weekly goals and self-monitoring health behaviors, and family communication and positive parenting/grandparenting content, all of which were developed in accordance with participant feedback based on formative intervention development work. In addition, and to increase participant compliance/reduce attrition often observed in digital health interventions, human support (supportive accountability) will be provided. Specifically, each family will be assigned a coach who will use video conferencing software to engage in weekly 15-30 minute sessions regarding the family's progress throughout the intervention period.
Study: NCT06502509

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Lemon tea
Description: Diluted lemon juice with the same pH as the commercial kombucha tea as placebo, which will be given to participants in opaque bottles for 8 weeks.
Study: NCT03215849

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: CRT-pacemaker device set to Routine Medical Therapy
Description: Medtronic Serena™ QUAD CRT-P MRI™ SureScan™ W4TR05 set to Routine Medical Therapy

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CRT-pacemaker device set to Routine Medical Therapy + LVP
Description: Medtronic Serena™ QUAD CRT-P MRI™ SureScan™ W4TR05 set to Routine Medical Therapy + LVP

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CRT-pacemaker device set to Routine Medical Therapy + BiVP
Description: Medtronic Serena™ QUAD CRT-P MRI™ SureScan™ W4TR05 set to Routine Medical Therapy + BiVP
Study: NCT05314101

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Participants will receive Tislelizumab, 200mg, intravenously over 30 - 60 minutes, day 1 of every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Participants will receive bevacizumab，5mg/kg，intravenously over 60 - 90 minutes, day 1 and day 15 of every 4 weeks
Study: NCT04623515

Intervention type: OTHER
Intervention: REDCap Questionnaires
Description: Once consent is obtained, the participants will be routed to a REDCap secure link. Participants will complete a questionnaires regarding demographics and medical history. Participants will also complete validated questionnaires regarding their lower urinary and bowel tract function and sexual health- International Consultation on Incontinence Questionnaire Female Lower Urinary Tract Symptoms (ICIQ-FLUTS), Modified Manchester Health Questionnaire (MMHQ), PROMIS® v2.0 Brief Profile Sexual Function and Satisfaction (Female) and SF-12 ® .

Intervention type: OTHER
Intervention: REDCap Questionnaires
Description: Once consent is obtained, the participants will be routed to a REDCap secure link. Participants will complete a questionnaires regarding demographics and medical history. Participants will also complete validated questionnaires regarding their lower urinary and bowel tract function and sexual health- International Consultation on Incontinence Questionnaire Female Lower Urinary Tract Symptoms (ICIQ-FLUTS), Modified Manchester Health Questionnaire (MMHQ), PROMIS® v2.0 Brief Profile Sexual Function and Satisfaction (Female) and SF-12 ® .
Study: NCT05625373

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vancomycin
Description: The powder will be placed within the surgical wound prior to skin closure.
Study: NCT06072092

Intervention type: DEVICE
Intervention: BIS Monitor
Description: No interventions will be administered, but in addition to the standard of care according to the Guidelines of the European Resuscitation Council 2021, a frontal EEG-monitoring (BIS), a CPRMeter and a FlowMeter will be installed. The study will be observational only; the readings of the BIS monitor will be blinded to the treating PRU team.
Study: NCT05433740

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Proseal Laryngeal mask fixation
Description: fixation with Proseal Laryngeal mask adjustable ligament
Study: NCT05432388

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: remibrutinib
Description: oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: remibrutinib
Description: oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: remibrutinib
Description: oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: remibrutinib
Description: oral tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: oral tablets
Study: NCT05688189

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: different starting temperature setting of HFNC
Description: The humidification temperature will be set based on the enrollment arm (37°C vs 34-37°C vs 31-34-37°C)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: different starting temperature setting of HFNC
Description: The humidification temperature will be set based on the enrollment arm (37°C vs 34-37°C vs 31-34-37°C)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: different starting temperature setting of HFNC
Description: The humidification temperature will be set based on the enrollment arm (37°C vs 34-37°C vs 31-34-37°C)
Study: NCT06489652

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 89Zr-Oxine-RY_SW01 Cell Injection
Description: Biodistribution and metabolic kinetic characterization of zirconium-labeled cells in vivo for the treatment of systemic sclerosis by intravenous infusion of 89Zr-Oxine-RY_SW01 cells injection
Study: NCT05671224

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Visual aid
Description: Handout and video describing different types of induction of labor
Study: NCT06489990

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: combination intervention strategy of [Comorbidity-Co-causes-Joint-prevention]
Description: combination intervention strategy of \[Comorbidity-Co-causes-Joint-prevention\]

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: routine health education and mental health knowledge
Description: routine health education and mental health knowledge
Study: NCT05314101

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAS-102
Description: Participants will receive TAS-102, 35mg/m2, bid，d1-d5, d8-d12 of every 4 weeks
Study: NCT06080854

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: Toripalimab 240mg administered intravenously on Days 1 of every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine 1000 mg/m\^2 administered intravenously on Days 1 \& 8 of every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab paclitaxel
Description: Nab paclitaxel 125 mg/m\^2 administered intravenously on Days 1 \& 8 of every 3 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SBRT
Description: SBRT Radiotherapy plan: Planning gross tumor volume (PGTV) 5Gy\*10 fractions, Planning target volume (PTV) 3Gy\*10 fractions
Study: NCT05076019

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80mg
Description: Dosage: 80 mg Form: Tablets Frequency: 1 tabl. per day. Duration: From 7 to 14 days prior to surgery until 30 days postoperative

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Form: Tablets Frequency: 1 tabl. per day. Duration: From 7 to 14 days prior to surgery until 30 days postoperative
Study: NCT05397587

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Experimental Vaccine
Description: The EV71 vaccine was manufactured by Sinovac Biotech Co., Ltd and inactivated EV71 virus antigen was no less than 3.0EU in 0.5 mL of aluminium hydroxide solution per injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Experimental Vaccine
Description: The EV71 vaccine was manufactured by Sinovac Biotech Co., Ltd and inactivated EV71 virus antigen was no less than 3.0EU in 0.5 mL of aluminium hydroxide solution per injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Experimental Vaccine
Description: The EV71 vaccine was manufactured by Sinovac Biotech Co., Ltd and inactivated EV71 virus antigen was no less than 3.0EU in 0.5 mL of aluminium hydroxide solution per injection.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Control Vaccine
Description: The EV71 vaccine was manufactured by Institute of Medical Biology,Chinese Academy of Medical Sciences ,and inactivated EV71 virus antigen was no less than 3.0EU in 0.5 mL of aluminium hydroxide solution per injection.